Protocol Ledger

NCT06880744 · Phase III · ACTIVE NOT RECRUITING

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Interventional Phase III clinical trial protocol NCT06880744 sponsored by AbbVie in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-17 Enrollment: 573 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06880744
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)573 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06880744
Protocol FieldVerified Registry Value
NCT IdentifierNCT06880744
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment573 participants (ACTUAL)
Registered Start Date2025-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI